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Nanoscale interactionArtiﬁcial antigen presenting cells (aAPCs) are engineered platforms for T cell activation and expansion, synthe-
sized by coupling T cell activating proteins to the surface of cell lines or biocompatible particles. They can serve
both as model systems to study the basic aspects of T cell signaling and translationally as novel approaches for
either active or adoptive immunotherapy. Historically, these reductionist systems have not been designed to
mimic the temporally and spatially complex interactions observed during endogenous T cell-APC contact,
which include receptor organization at both micro- and nanoscales and dynamic changes in cell and membrane
morphologies. Here, we reviewhowparticle size and shape, aswell as heterogenous distribution of T cell activat-
ing proteins on the particle surface, are critical aspects of aAPC design. In doing so, we demonstrate how insights
derived from endogenous T cell activation can be applied to optimize aAPC, and in turn how aAPC platforms can
be used to better understand endogenous T cell stimulation. This article is part of a Special Issue entitled:
Nanoscale membrane organisation and signalling.
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Artiﬁcial antigen presenting cells (aAPCs) are engineered platforms
for T cell activation and expansion. By replacing and recapitulating the
functions performed by endogenous antigen presenting cells, aAPCs
serve as cost-effective alternatives to cellular APC for immunotherapy
and as minimalist cell-free systems for studying T cell activation.
aAPCs are synthesized by coupling necessary T-cell stimulating pro-
teins, such as co-stimulatory proteins and Major Histocompatibility
Complex (MHC)/Human Leukocyte Antigen (HLA) loaded with antigen
of interest to the surface of an appropriate solid support. aAPCs have
been built upon a wide variety of biocompatible platforms, including
cultured cell lines, liposomes, and biodegradable polymer particles,
and have been functionalized with a variety of proteins that deliver T
cell activating signals [1].
These simpliﬁed systemsprovide theminimumnecessary signals for
T cell stimulation, leading to robust T cell activation and expansion.
However, as reviewed in this issue and elsewhere [2,3], it is becoming
increasingly clear that T cell–APC interactions are temporally andle membrane organisation and
gy, Johns Hopkins School of
05, USA. Tel.: +1 410 614 4589.spatially complex, with dynamic changes in the lateral organization of
surface receptors on both the T cell and APC. Membrane heterogeneity,
receptor clustering, and activation-induced membrane rearrangements
on several scales are part of a complex molecular machine that under-
scores T cell activation [4].
This complexity is both a challenge and an opportunity for the
biomedical engineer. On one hand, it is precisely the complexmolecular
mechanisms that underlie T cell receptor function and enable its
precision and sensitivity. On the other hand, it is becoming clear that
engineered platforms meant to activate immunity are capturing only
the most rudimentary interactions that occur during T cell activation.
Here, we review our current understanding of the biophysical and
spatial aspects of the T cell-APC interaction and its application to aAPC
design. In doing so, we demonstrate how insight into the nature of T
cell activation by aAPC ﬂows in both directions. Artiﬁcial platforms for
T cell activation can serve as models to better understand the endoge-
nous system, and this knowledge can, in turn, be adapted for improved
translational platforms for immunotherapy.
2. The Signal 1 + 2 paradigm in aAPC design
A general paradigm for the design of aAPC has been tomimic endog-
enous T cell activation by selecting T cell activating signals that lead to
optimal stimulation. In the healthy host, these are provided by endoge-
nous APC such asmacrophages, B cells and dendritic cells (DCs). In aAPC
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binant proteins to an aAPC platform that can then trigger responses
from receptors on the T cell membrane. Studies of T cell activation by
aAPC have demonstrated that two signals, termed Signal 1 and Signal
2, are minimally necessary to trigger robust expansion of highly
functional T cells (Fig. 1).
2.1. Signal 1
Signal 1 is mediated by the interaction of TCR on the T cell with pep-
tide presented byMHC on the APC. Peptide-bearingMHC preferentially
interacts with T cell receptors speciﬁc for one or several MHC–peptide
combinations, and thus Signal 1 determines the speciﬁcity of the T cell
response for a given epitope.MHC-binding to TCR triggers the activation
of the TCR-associated CD3 signaling complex through as-of-yet incom-
pletely understood mechanisms [5,6]. In aAPC design, Signal 1 can be
provided by either MHC-peptide binding to TCR, or by engaging the
CD3 complex directly with an anti-CD3 antibody (Fig. 1).
Soluble Class I and Class II MHC proteins can be produced
recombinantly and loaded with appropriate peptide for a variety of
antigens of interest. The aAPC engineer must select an MHC allele and
peptide that induce a T cell response against the antigen of interest. In
humans, HLA-A2*01 has been most frequently studied, based on its
high frequency among people of Northern European and American
descent. In mice, Kb and Db alleles, as well as Ld, are frequently used
based on their presence in the common laboratory strains C57BL6/J
and Balb/c, respectively. Following stimulation, the yield and frequency
of antigen-speciﬁc cells can be monitored using soluble, multimeric
MHC reagents.
Alternatively, Signal 1 can be provided by an antibody against the
CD3 signaling complex. A variety of activating CD3 antibodies are avail-
able, including theOTK3 clone in humans and 145-2C11 inmice. Impor-
tantly, activation via CD3 triggers non-speciﬁc expansion of all T cells,
including regulatory T cells and cells reactive against irrelevant anti-
gens; over time, this can result in preferential expansion of irrelevant
cells and reduced activity against the target. Thus, for most applications,
a source of T cells enriched for activity against the antigens of interest is
desired. In cancer immunotherapy, tumor inﬁltrating lymphocytes can
provide such a source of anti-tumor activity [7], or antigen-speciﬁc
cells can be puriﬁed from Peripheral Blood Mononuclear Cells or other
polyclonal sources by HLA-tetramer-based enrichment prior to poly-
clonal expansion [8]. Unfortunately, anti-CD3/anti-CD28 aAPC have
only shown the ability to expand and sustain CD4 [9] but not CD8 T
cell cultures [10,11] without additional feeder cell support, making
them an appropriate choice only when CD4 cells are required, or
when the additional cost and labor associatedwith culturing autologous
feeder cells can be tolerated.Fig. 1. The Signal 1+ 2 paradigm. Endogenous APC presents two necessary and sufﬁcient signal
Signal 2 comprises numerous activating and inhibitory co-stimulatory ligands that bind recepto
polyclonally activating anti-CD3 antibody as Signal 1, and either activating antibodies against
B7.1 (rB7.1).2.2. Signal 2
Signal 2, the co-stimulatory signal, is a series of interactions between
receptors on the APC and T cell surface that modify TCR signaling by
providing both activating and/or inhibitory signals. The prototypical in-
teraction, between B7.1/B7.2 on the APC and CD28 on the T cell surface,
leads to optimal T cell expansion. If Signal 1 is engaged in the absence of
Signal 2 in vitro, CD4+ T cells enter a state of anergy, in which T cell
proliferation and effector function after re-stimulation are limited [12].
Ineffective Signal 2 stimulation can also lead to the development of
suppressive T cells, and the balance between anergy and regulatory
development is an area of active study.
Several activating Signal 2 interactions have been identiﬁed, in-
cluding the B7 family proteins B7.1 and B7.2, and their cognate T
cell receptor CD28; and the tumor necrosis factor receptor (TNFR)
family ligands OX-40L, CD70, 4-1BBL, which interact with OX-40,
CD27, and 4-1BB on the T cell, respectively. Certain Signal 2 interactions
can also be inhibitory to T cell expansion and effector function, such
as the interaction of CTLA-4 with B7.1 or PD-1 with PD-L1 (B7.H1) or
PD-L2 (B7-DC) [13].
In aAPC design, Signal 2 can be provided by coupling one or more of
the aforementioned APC receptors to the surface of an aAPC platform
(Fig. 1). In practice, activating antibodies against co-stimulatory T cell
receptors, such as the anti-mouse CD28 antibody 37.51, have been
shown to be an effective replacement for more costly recombinant
APC proteins [14]. While the downstream signaling mechanisms of
each co-stimulatory receptor vary, engagement by certain “activating”
antibody clones appears to be a near-universal mechanism for trigger-
ing co-stimulatory receptor activation.
Minimally, the addition of anti-CD28 antibody is required to design
effective aAPC that induce robust T cell proliferation [15,16] and main-
tain the full complement of T cell effector functions [16,17]. Under cer-
tain conditions of extremely strong Signal 1 activation, robust
expansion can be observed with Signal 1 alone [18], but the precise
phenotypic characteristics of such T cells and their effectiveness in
immunotherapy have not been described. On the other hand, many
platforms instead rely on multiple co-stimulatory signals delivered
simultaneously [19].
The precise signals delivered by each Signal 2 are likely to differ, and
thus the choice of Signal 2 protein may be an important parameter in
optimizing aAPC for a given application. For example, 4-1BBL may be
more effective than anti-CD28 as an activating signal for memory CD8
T cell expansion [20,21], or even synergize with simultaneously pre-
sented anti-CD28 [22]. The role of inhibitory signals has been explored
to a lesser extent; the addition of a PD-L1 to aAPC does not appear to
decrease T cell proliferation [23], but may have a role in shaping the
subsequent response.s for T cell activation. Signal 1 is cognate peptide presented in the context ofMHC, whereas
rs on T cells. aAPCs are synthesized by coupling either speciﬁcMHC–peptide complexes or
co-stimulatory molecules such as CD28 or recombinant co-stimulatory molecules such as
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In addition to the classic description of Signal 1 + 2, Signal 3 has
been coined as a catch-all term for a variety of soluble signals released
by APC that inﬂuences T cell activation and development. These include
lymphotropic cytokines such as IL-2, IL-7, and IL-15; inﬂammatory sig-
nals such as TNF-α; and cytokines which modulate T cell development
such as TGF-β, IL-12, IL-4, and IL-5. The precise effect of each of these
signals is beyond the scope of this review, but the cytokine milieu
released by APC before and during T cell activation is a critical determi-
nant of T cell development after activation [24–26].
During in vitro T cell stimulation by aAPC, the addition of exogenous
IL-2 is required for robust T cell expansion [27–29]. Alternatively, prolif-
eration can be supported by a variety of common gamma chain cyto-
kines, such as IL-7, IL-15, and IL-21, which may have the further
beneﬁt of maintaining T cell replicative potential and inducingmemory
formation compared to IL-2 [30,31]. These cytokines have been added to
aAPC-stimulated cultures to generate cells more amenable to tumor
immunotherapy [32]. IL-12 and Type 1 interferons added to culture
can support proliferation at low to intermediate antigen doses, and
the development of full effector function at any antigen dose [33–35].
There may be a further beneﬁt to delivery of Signal 3 directly from
aAPC rather than addition to culture, which could increase local cyto-
kine concentration at the T cell-aAPC interface, spatially co-localize all
3 T cell stimulatory signals, and deliver cytokines to the appropriate
site after in vivo administration. Thus far, application of Signal 3 in
aAPC design has been limited by the capabilities of aAPC platforms.
However, recent developments in design of aAPC based on biodegrad-
able polymers, which can release encapsulated proteins in a spatially
localized manner during hydrolytic degradation, have shown that IL-2
delivery from aAPC can signiﬁcantly enhance T cell proliferation
in vitro [36–38]. This “paracrine” delivery was ten-fold more effective
in inducing T cell expansion than the same overall dose of IL-2 in the
culture media [37].
3. Fixing signals to a solid substrate
aAPCs are constructed by coupling T cell activating proteins de-
scribed in the previous section to a suitable, biocompatible platform.
While multimerized, soluble MHC can induce some degree of T cell
activation [39–41], large numbers of MHC molecules are required per
T cell [42–45]. In contrast, as few as 10 cognate MHC presented on an
APC cell surface can be sufﬁcient to induce activation [46,47]. Similarly,
ﬁxingMHC-peptide (pMHC) or anti-CD3 to a physical substrate, such as
a latex bead, liposome, or microplate surface, signiﬁcantly enhances the
strength of T cell stimulation [40,48–52].
This solid substrate enhancement points to fundamental questions
about themechanism bywhich TCR is triggered byMHC, which despite
recent advances remains an open area of study. Two models, here
termed “mechanical triggering” and “rapid re-binding,” may explain
this phenomenon. A third complementary model, spatial segregation,
will be discussed in detail in subsequent sections.
During T cell activation, ﬂuctuations of the APC membrane can gen-
erate a pico- to femtonewton force on the T cell membrane [53]. These
forces can also be triggered by a timed series of active pushing and
pulling processes on the T cell [54]. Mechanical forces in this range in-
duced by micromanipulation of TCR by pMHC or clonotypic antibodies
are sufﬁcient to trigger downstream signaling responses in T cells [55,
56], and mechanical signals between T cells and APC enhanced by
shear ﬂow triggered stronger T cell stimulation in vitro [57]. Thus,
“mechanical triggering” of the TCR has been proposed as a model of
TCR activation by MHC, and may play a signiﬁcant role in signal
transmission.
The ﬁxing of soluble MHC to a solid substrate allows the transmis-
sion of mechanical forces from a cell or microparticle surface. This is
reﬂected in the dependence of T cell activation on substrate rigidity,with the strongest activation of mouse T cells triggered by ligands
presented on polymer substrates with elastic moduli greater than
10–200 kPa [58]. Interestingly, with human T cells, it was noted that
elastic moduli signiﬁcantly above this range impeded stimulation [59],
a ﬁnding attributed to decreased bond lifetimes under greater loading
force [60]. While TCR interactions with anti-CD3 antibody generated
the primary traction forces mediated by T cells, engagement of CD28
enhances the TCR associated force via an intracellular signaling pathway
mediated by PI3K [61].
Secondly, ﬁxation of Signal 1 to a solid support constrains the
receptor–ligand interaction to a planar cell-surface interface and allows
for rapid re-binding of cell surface receptors. During physiological T cell/
APC interactions, receptors are conﬁned to the two-dimensional axis of
cell-cell contact. In contrast, biophysical measurements of TCR–MHC in-
teractions have traditionally been made by characterizing binding of
soluble MHC dimers or antibodies measured either by ﬂow cytometry
or surface plasmon resonance, which involve a third degree of freedom.
“Two dimensional” measurements that more closely re-capitulate
TCR–MHC interactions at the cell-cell membrane can be made by
assessing interactions of a T cell with an MHC-coated particle [62,63],
similar in design to an aAPC. 2D afﬁnity analysis has resulted in the
identiﬁcation of a wider range of cognate T cell ligands [64,65].
Measurements in two dimensions broadly agree with kinetic binding
parameters measured in situ, which show large increases in both
association (100-fold) and disassociation (4–12 fold) compared to
measurements in solution, ultimately resulting in increased overall
afﬁnity [66].
This enhanced 2D afﬁnity, and particularly enhanced on-rate from
constrainedMHC, has led to a “rapid re-binding”model, wherein strong
pMHC agonists conﬁned to the surface efﬁciently rebind the same or
neighboring TCR within individual receptor nanoclusters [63,65–68].
Compared to on-rates driven primarily by MHC diffusion, re-binding
that takes place in a constrained two-dimensional membrane is signiﬁ-
cantly enhanced. In this model, the assembly of downstream signaling
ligands can tolerate brief loss of contact between TCR and MHC as
long as the receptor is efﬁciently rebound. Thus, the ability of cognate
MHC-peptide to trigger TCR activation depends not only on the kinetic
off-rate, as had been proposed by earlier models [69], but also the on-
rate-the ability of MHC to re-bind the same or neighboring [68,70] TCR.
MHC can be ﬁxed to a number of different platforms, from easily cul-
tured cell lines to biodegradable polymer scaffolds.While different plat-
forms possess different mechanical and surface properties, the most
commonly used substrates all share in common biocompatibility and
ease of synthesis. The earliest platforms were APC-like cells based on
cultured cell lines [71,72], particularly the K562 human erythromyeloid
line [19,20,73–76] and the murine NIH/3T3 ﬁbroblast line [77–79],
engineered to express Signal 1 and Signal 2. Among the earliest cell-
free platforms used for T cell activation were liposomes, spherical vesi-
cles with an aqueous interior generated by self-assembly of amphiphilic
phospholipids and cholesterol, also modiﬁed to express the relevant T
cell-activating signals [50,51,80–83].
Synthetic substrates have the additional beneﬁt of having tunable
mechanical, geometrical, and biodegradable properties, either by
adjusting the synthesis method or base material. Sepharose [84,85]
and latex (polystyrene) beads [10,28,86–89] were the ﬁrst synthetic
bead-based platforms used in aAPC design, and have been instrumental
as reductionist systems for studying basic aspects of T cell biology. Iron-
dextran microparticles have also been extensively characterized as
aAPC, both for translational applications of tumor-speciﬁc T cell expan-
sion [15,90] and as a tool for the study of basic aspects of T cell antigen
recognition and development [91–94]. Additionally, microparticles can
be synthesized from a variety of biodegradable polymers, such as poly
(lactic acid) (PLA), poly (glycolic acid) (PGA), and their co-polymer,
poly (lactic-co-glycolic acid) (PLGA) and used for antigen-speciﬁc T
cell activation [38,95], with signiﬁcant biocompatibility advantages
over non-degradable platforms such as polystyrene.
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Thus far, the primary focus of aAPC design has been the selection of
T cell stimulating signals and platforms to which they are coupled.
However, it has become evident that receptor organization between
the T cell and APC plays an additional important role in endogenous
activation. Recapitulating and even enhancing this aspect of T cell
activation represents a new frontier in optimal aAPC design. Here, we
will brieﬂy review relevant spatial considerations of natural T cell-APC
interactions.
The idea that spatial organization of the TCR and accessory signaling
proteins plays a critical role in T cell activation gained support with the
discovery of the immune synapse [96], a micro-scale cell–cell interac-
tion structure formed during activation of T cells by APC. During im-
mune synapse formation, adhesion molecules such as LFA-1 migrate
to the periphery of the T cell contact site, the peripheral supramolecular
activation cluster (pSMAC), whereas TCR, CD3, and other signaling
proteins are found in the central SMAC (cSMAC) [97] (Fig. 2). TCR
nanoclusters form at the periphery of contact and traverse toward the
cSMAC [98] where they are subsequently degraded. However, the
discovery of the synapse was soon followed by studies showing that
synapse formation, which occurs minutes after T cell-APC contact, was
preceded by strong TCR signaling from TCR nanoclusters and was thus
only a piece of the T cell activation puzzle [99]. Today, it is appreciated
that the nature of the synapse varies with the strength and duration of
stimulus, the activation state of the T cell, and the nature of the APC
[100]. Additionally, the synapse can perform numerous functions,
from turning off signaling [101] to providing a cell–cell contact zone
for exchange of cytokines and cytotoxic granules [102].
Fundamental insights into the nature of the synapsehave beenmade
using planar lipid bilayers, acellular T cell activation platforms similar in
concept to aAPC (reviewed in [103]). Planar synthetic surfaces can be
designed using numerous techniques, most commonly by inserting
freely diffusible, GPI-anchored T cell activating proteins into lipid mem-
branes coated onto glass slides. The ﬂat contact surface allows the use of
imaging techniques with high spatial and/or temporal resolution such
as total internal reﬂection microscopy [104], as well as control over
activation parameters such as ligand strength and density.
New surface fabrication techniques allow T cell activating ligands to
be patterned in precisely controlledways on planar bilayers, providing a
tool to study the effect of microscale APC membrane organization on T
cell activation. For example, the presence of anti-CD28 at the peripheryFig. 2. Scales of organization. T cellmembrane organization at several scales contributes to
signaling and activation. TCR is pre-clustered in 15–30 nm nanoclusters prior to T cell
activation, particularly on the surface of previously activated or memory cells. Upon
MHC binding, 35–70 nm signaling nanoclusters form and drive downstream signaling.
These clusters migrate to the center of the T cell–APC contact site, forming the cSMAC,
and are subsequently internalized and degraded. Adhesion molecules such as LFA-1 are
distributed in the pSMAC, which together with the cSMAC forms the micron-scale
immune synapse.of the T cell contact site on planar arrays containing anti-CD3, CD28, and
ICAM-1 signiﬁcantly enhanced IL-2 secretion anddownstream signaling
by mouse CD4 T cells [105]. Similarly, mechanically trapping TCR
nanoclusters at the peripheral regions of a forming synapse signiﬁcantly
prolonged and strengthened signaling from TCR nanoclusters [106].
However, separation of anti-CD3 and anti-CD28 contact sites by several
microns in human T cells curtailed co-stimulatory activity [107]. Thus,
while existing aAPC fabrication techniques generally rely on randomly
distributed ligands, these ﬁndings suggest that it may be possible to
ﬁne-tune T cell activation from aAPC by patterning activating ligands
in ways that mimic T cell–APC interaction. However, this will require
the development of technologies for heterogeneous ligand distribution
on particle surfaces [108,109] (Fig. 3A).
More effective aAPC mediated stimulation may also be possible by
mimicking the micro-scale, cytoskeletal membrane rearrangements
that occur at the T cell–APC interface. T cells have a sensitive leading
edge thatmakes primary contactwith APC, triggering a cell–cell interac-
tion program [110] that leads to cellular ﬂattening and an augmented
area of surface contact [111]. Simultaneously, cytoskeletal rearrange-
ments in the APC drive membrane polarization [112] and increased
surface contact.
In contrast, most synthetic aAPC platforms are spherical, a shape
which is easily synthesized using standard chemical synthesis proce-
dures such as double-emulsion of PLGA [113]. This geometry not only
fails to recapitulate APC membrane dynamics observed during activa-
tion, but also minimizes the surface area and maximizes the curvature
at the T cell–aAPC interface. Recently, we utilized a novel particle
fabrication method to control microparticle geometry with deﬁned
MHC dose and density [114]. Compared to spherical aAPC, ellipsoidal
aAPC with increased aspect ratio and surface area preferentially
engaged cognate T cells, with T cells observed to favor engaging aAPC
along their long axis (Fig. 3B). This interaction was reﬂected in en-
hanced T cell expansion and in vivo tumor killing activity after stimula-
tion by ellipsoidal aAPC and highlights the importance of geometry
considerations in aAPC design. Similar synthesis techniques could be
used to mimic additional membrane geometries relevant to T cell–APC
interactions, such as membrane protrusions/lamellipodia that enhance
close membrane apposition [115].
Particle geometry also inﬂuences uptake by the reticuloendothelial
system, an important consideration for aAPCs that are directly adminis-
tered in vivo. Ellipsoidal particles with a long characteristic axis show
reduced phagocytosis [116–119]. Interestingly, receptor-mediated in-
ternalization of antibody coated non-spherical particles is signiﬁcantly
enhanced, suggesting that the interaction of geometry and uptake
may be pathway dependent [120]. These contrasting properties of
identically shaped aAPC may be used to their advantage to prolong cir-
culation time where receptor-mediated internalization is preferred,
such as in drug delivery applications. In either case, in vitro uptake
studies may not mimic in vivo behavior; adsorption of complement
and other serum proteins signiﬁcantly alter trafﬁcking and clearance
characteristics of in vivo administered aAPC.
5. Nanoscale clustering and nanoscale aAPC
Upon engagementwith cognate antigen, TCRmicroclusters, estimat-
ed to be 35–70 nm in diameter and containing 7–20 TCR [121], form at
the periphery of the T cell-APC contact site (ﬁrst described in [122] and
reviewed in [2]). These clusters are enriched for signaling molecules
such as Lck, Zap-70, Lat, and SLP76, suggesting that they are directly
involved in T cell signaling. Microcluster formation precedes but is
associated with synapse formation, as both involve a cortical F-actin
ﬂow that leads to inward migration of TCR.
Spatial heterogeneity in membrane organization and TCR cluster-
ing can be detected even in the absence of stimulation by cognate an-
tigen. Using immunoprecipitation and immunoblotting techniques,
Fernandez-Miguel et al. demonstrated that the αβ T cell receptor can
Fig. 3. Scales of organization. A. Studies from patterned lipid bilayers suggest that T cells preferentially activate against surfaceswithMHC–peptide (purple) forming the center of the con-
tact site, and anti-CD28 (orange) distributed in theperiphery. In contrast,most aAPCs are synthesizedwith uncontrolled protein distribution. B. Ellipsoid rather than sphericalmicro-aAPCs
provide a greater surface area and decreased surface curvature for optimal T cell engagement, leading to enhanced antigen-speciﬁc T cell activation and proliferation. C. Nanoscale aAPCs,
less than 100 nm indiameter, have recently been shown to be capable of activating T cells. These nano-aAPCs (orange) can “sense”nanoscale TCR distribution, as they preferentially bind to
activated T cellswhich havemore clustered TCR (purple) than naive cells. This leads to higher avidity for aAPC binding, but fewer aAPC bound to each T cell, since each aAPC bindsmultiple
TCR. This effect enhanced activation of activated cells by nano-aAPC, whereas this preference was not observed with micro-aAPC.
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two TCR and a higher order CD3 stoichiometry [123]. TCR likely
exist in several distinct monovalent and multivalent forms prior to
antigen engagement [124], with the number of TCR in a cluster
prior to activation ranging from a single receptor to 20 [125] within
clusters that are 15–30 nm in diameter [126]. Although both TCR clus-
ters formed prior to and after antigen engagement are generally less
than 100 nm in diameter, the former have been termed “nanoclusters,”
and the later, “microclusters.” The precise relationship between these
structures has not been fully elucidated; however, it is possible
that TCR nanoclusters concatenate to form the larger activation
microclusters that are observed by TIRF [121]. Thus, receptor organiza-
tion at bothmicro- and nanoscales play a central role in T cell activation
(Fig. 2).
In parallel, spatial heterogeneity of MHC on the APC surface mirrors
the T cell membrane. Near-ﬁeld scanning techniques have resolved
protein-rich “patches” of MHC with radii between 70 and 600 nm on
the surface of resting APC [127], containing approximately 25–125
MHC each. During antigen processing, MHC bearing peptides derived
from a given pathogen are deposited as a cluster on the APCmembrane
[128–130], generating peptide-speciﬁc clusters that facilitate interac-
tion with peptide-speciﬁc TCR. Subsequently, during T cell activation,
MHC moves in concert with their binding partners to form clusters in
the cSMAC zone of the APC, with adhesion molecules such as ICAM-1
migrating to the pSMAC. These pre-formed clusters and subsequent
movements are controlled by the intricate interactions of lipid and pro-
tein domains, such as lipid rafts and tetraspanin domains in the mem-
brane [131], as well as protein interactions with the actin cytoskeleton
[131].
Spatial rearrangements may serve as a critical piece of the mecha-
nism behind T cell triggering after engagement by cognate MHC [132].A common element in spatial activation models is kinase concentration
and phosphatase exclusion— phosphorylating proteins are concentrat-
ed in the region that contains their substrate, whereas dephosphorylat-
ing proteins are excluded, tipping the local balance in favor of signal
transduction. Consistent with this hypothesis, it was recently shown
that close apposition between the T cell and APC membrane drove ex-
clusion of proteins such as the phosphatase CD45, whereas the binding
energy between TCR and pMHC was sufﬁcient to keep these pro-
teins within the central contact area [5]. This mechanism was sufﬁ-
cient for T cell signaling in a reconstituted system. Furthermore,
new high-resolution imaging techniques have demonstrated nano-
scale co-localization of TCR and downstream signaling proteins, which
is enhanced after cognate pMHC binding [121]. Furthermore, spatial co-
localization may play a complementary role with other activation
models, including induction of conformational changes in the TCR–
CD3 complex that initiate downstream activation [133].
Receptor clustering prior to ligand engagement can be a higher order
mechanism which enhances binding and sensitivity. For example, clus-
tering of chemo-receptors on Esherichia coli signiﬁcantly lowers the
threshold and enhances the dynamic range of chemotactic responses
[134]. Preliminary evidence suggests that such clustering may be par-
tially responsible for the high degree of T cell sensitivity to antigen;
for example, only multivalent but not monovalent TCR/CD3 complexes
were phosphorylated after stimulation with a low dose of antigen
[125,135]. Enhanced clustering after activation may also partially ex-
plain the increased sensitivity of previously activated T cells to antigen
[136,137], acting in concert with changes in downstream signaling
[138]. Similarly, clustering MHC on an APC surface augments T cell
recognition [139]. Thus, receptor organization likely plays a signiﬁcant
role in the exquisite sensitivity and speciﬁcity of the TCR–MHC interac-
tion, motivating its careful consideration in aAPC design.
786 K. Perica et al. / Biochimica et Biophysica Acta 1853 (2015) 781–7905.1. MHC valency and density
With the importance of MHC clustering and spatial organization in
endogenous T cell activation, it is no surprise that this parameter has
been carefully explored for the design of artiﬁcial T cell activation plat-
forms. Soluble MHCmonomers, separated from their natural context in
the APC membrane, have low, micromolar afﬁnity for cognate TCR. This
prompted the development of multimeric MHC constructs such as di-
mers and tetramers, which enhance overall binding avidity [140,141].
T cell triggering by these soluble multimeric MHC is highly dependent
on intramolecular distances between MHC within the protein construct,
with shorter intramolecular cross-linkers being signiﬁcantly more effec-
tive than longer cross-linkers, and a signiﬁcant decrease in stimulatory
activity occurring at a distance of approximately 8 nm [142].
By analogy, while monomeric MHC coupled to aAPC microspheres
can trigger T cell activation [48,88], studies with multivalent MHC sug-
gest that multivalency induces stronger responses [49,143]. However,
no comprehensive examination between such constructs has been
performed. Furthermore, multivalent MHC constructs can have other
biophysical disadvantages: commonly used MHC tetramers have been
coupled aAPC [144–146], but their rigid tetrahedral geometry orients
a fraction of MHC molecules toward the particle surface and conse-
quently away from the interacting T cell.
A similar effect toMHCmultivalencymay bemediated by controlling
density of monomeric MHC proteins on an APC surface. Antigen density
on APC membranes is known to affect subsequent T cell response
[147–150]. This principle may also apply to aAPC design, although anti-
gen presented on aAPC is often presented at supraphysiologically high
doses compared to the small numbers of cognate MHC-peptides that
trigger T cell activation.
On planar lipid arrays functionalized with anti-CD3 antibody in a
controlled and homogenous fashion, anti-CD3 spacing of less than
70 nm is required to observe T cell activation [151]. Using peptide-
MHC “corrals” patterned on lipid arrays, the Groves group demonstrat-
ed that thresholds for T cell triggering are determined by the number of
activating ligands available to individual TCR clusters, not the total
MHC available to the entire cell [152]. A similar density threshold is ob-
served for monomeric MHC presented on spherical microparticles, and
the addition of more beads at a sub-threshold density is not sufﬁcient
to overcome this effect [10,49]. Additionally, the density of MHC may
control the avidity of the resulting cultured T cells, with an inverse rela-
tionship between T cell avidity and MHC density. Higher avidity T cells
result from aAPC with a lower MHC density, likely via clonal competi-
tion, and high density aAPC increases activation of low-avidity clones
[153]. Thus, if high avidity T cell responses are desired, investigators
must titrate density to achieve a balance between T cell quantity and
quality.
Furthermore, there may be advantages to manufacturing aAPC with
heterogenous or clustered protein signals whichmimic the distribution
of MHC on endogenous APC membranes. One study used anti-CD3,
−CD28, and −LFA-1 monoclonal antibodies pre-clustered on lipo-
somes using neutravidin rafts to efﬁciently activate MART-1 speciﬁc
CD8 T cells [50], although the precise role of clustering in enhancing T
cell responses could not be clearly deﬁned. In a separate liposome-
based study, CD4 stimulation was signiﬁcantly stronger from aAPC
presenting clustered compared to unclusteredMHC [154]. A high densi-
ty (5–8 nm separating distances) of clustered non-cognate MHC pre-
sented on the surface of nano-sized quantum dots is required to
enhance binding and activation by cognate pMHC [155], a ﬁnding that
may explain conﬂicting results obtainedwith the “pseudo-dimer” theo-
ry, which states that numerous weak binding events with non-cognate
MHC augment less frequent strong binding eventsmediated by cognate
MHC.
Further application of heterogeneous MHC clustering on aAPC will
require the development of biocompatible, readily synthesized plat-
forms with spatially controlled receptor patterning [109]. For example,the Little group recently reported a technique based on interfacial con-
densation of a liquidmask to createmicrosphereswith “patchy” protein
islets [156].
5.2. Nanoparticle aAPC can activate T cells and sensemembrane organization
Studies on synthetic bead-based aAPC have largely focused on the
development of cell-sized, micro-scale aAPC in order to better mimic T
cell interactionwith antigen presenting cells. This choice is theoretically
reinforced by microscale T cell–APC interactions described above.
In fact, early studies by the Mescher group suggested that only bead-
based aAPCs larger than 2 μm in diameter are able to induce T cell
proliferation [88,157]. Steenblock et al. [38] demonstrated that
polymer-based nanoparticles weremuch less efﬁcient thanmicrobeads
in inducing short-term functional responses, with no reported prolifer-
ation. However, recent discoveries of TCR organization at the nanoscale
re-ignited interest in developing nano-sized aAPC particles, which
might theoretically be able to interact with individual TCR nanoclusters
to stimulate T cells and “sense” TCR distribution.
Several publications have now demonstrated that nanoparticles
less than 100 nm in diameter can trigger robust T cell activation. For
example, our group developed “nano-aAPC” by coupling dimeric
MHC-immunoglobulins and anti-CD28 to the surface of iron-dextran
nanoparticles. These nano-aAPCs are able to induce robust T cell expan-
sion in vitro and have signiﬁcant advantages over micron-sized parti-
cles. Unlike microparticles, nanoparticles of approximately 50–100 nm
diameter can be transported by lymphatics to the lymph nodes [158,
159], thus gaining access to a larger pool of T cells. Enhanced drainage
of 50–100 nm aAPC compared to micron sized aAPC was observed in
our hands [160], although even smaller nanoparticles may be required
for optimal lymphatic transport [161]. In addition, nanoscale delivery
vehicles may preferentially accumulate in tumors through the en-
hanced permeability and retention effect which is attributed to the
tumor's tendency toward leaky vasculature and poorly organized lym-
phatic drainage [162,163]. By delivering an immunostimulatory signal
in situ, aAPC in the tumor microenvironment may address one of the
most prominent hurdles in cancer immunotherapy, the immunosup-
pressive tumor microenvironment [164].
In addition to inducing antigen-speciﬁc T cell activation, nano-aAPC
binding to TCR nanoclusters can be used to gain qualitative information
on TCR clustering of T cells in various physiological states, such as
naive and activated cells. In particular, TCR undergo a state-dependent,
persistent increase in the extent of TCR clustering days to weeks after
activation. Binding assays using dimeric MHC-Ig fusion proteins
demonstrated that T cells activated four days previously showed en-
hanced binding of low concentrations of MHC, with a high degree of
cooperativity [136,140]. Since this effect was not observed with mono-
valent MHC, the authors determined that a higher degree of clustering
led to the enhanced binding of MHC dimers. Persistent TCR clusters on
activated cells was directly visualized using electron [137] and k-
Space Image Correlation microscopy [165], with a distinct increase in
clustering noted as compared to naive cells.
Differences in TCR clusteringmodify the T cell's ability to bind to and
be activated by cognate pMHC. CD3 functionalized nanoparticles prefer-
entially augment the expansion of antigen-experienced but not naive T
cells that are concurrently stimulated with endogenous APC [166]. Re-
cent work by our group demonstrates that nano-aAPC favors binding
to clusters which are characteristic of activated rather than naive CD8
T cells [167]; furthermore, by exploiting the paramagnetic properties
of iron-dextran nanoparticles, we demonstrated that magnet induced
clustering of the cell-bound nanoparticles, and consequently their asso-
ciated TCR clusters, was sufﬁcient to induce robust activation of other-
wise poorly sensitive naive T cells. This technique can be used to boost
nano-aAPC mediated activation of naive T cells, and suggests an addi-
tional mechanism by which T cells more efﬁciently detect cognate
antigen subsequent to activation.
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Despite these insights into the complex interactions underscoring T
cell activation, most aAPC designs remain straightforward applications
of the Signal 1 + 2 paradigm, with T cell activating proteins ﬁxed in
an uncontrolled manner to spherical microscale particles. This choice
reﬂects the ease and simplicity of developing such systems, but does
not reﬂect the rapid pace at which our understanding of T cell-APC
interactions is advancing.
aAPCs have been utilized as therapeutic platforms primarily in one
of twoways. The ﬁrst, direct vaccination, involves the direct administra-
tion of aAPC into a host, where aAPCmust trafﬁc to and co-localize with
host T cells. The earliest reports of this approach involved 5 μmdiameter
silica microbeads coated with MHC-antigen but no Signal 2, injected
intraperitoneally into tumor-bearing mice [48]. However, no antigen-
speciﬁc responses or tumor activity could be detected unless a cell-
based tumor vaccine was co-administered, suggesting that aAPC could
only boost an existing response. This platform was subsequently
assessed in a Phase I trial of patients with disseminated melanoma
[168], with 8/15 patients developing antigen-speciﬁc cytolytic T cells,
but only one partial tumor response. In mice, iron-dextran micro-aAPC
bearing dimeric MHC-peptide and anti-CD28 injected intravenously
[15] canmediate regression of both subcutaneousmelanoma and intra-
venous lung metastases. Similarly, latex particles administered both
intravenously and subcutaneously generated robust antigen-speciﬁc T
cell responses inmice, and subcutaneously administeredmicroparticles
mediated B16 melanoma rejection [146].
This approach is particularly relevant to disease states like cancer,
where endogenous antigen-presenting mechanisms are defective
[169–171] and therefore motivate a desire to replace or supplement
the endogenous APC compartment. Within the tumor microenviron-
ment, APC can go beyond dysfunction to active immune inhibition
[172–174]. Thus, even if antigen is delivered in a vaccine platform to
the host APC, it may not lead to T cell activation, motivating the use of
aAPC in vivo.
Thus, induction of tumor-speciﬁc cytolytic T cells does not necessar-
ily correlate with tumor regression in human studies, a ﬁnding at least
partially attributed to the suppressive mechanisms of the tumor micro-
environment. Direct vaccination with aAPC therefore has signiﬁcant un-
explored potential, particularly as immunomodulatory strategies such as
“checkpoint blockade” are developed to temper these suppressivemech-
anisms that doomed the ﬁrst generation of cancer vaccines [175].
Considerations of aAPC size and shape are likely to feature prominently
in this approach, as they inﬂuence both the in vivo trafﬁcking and subse-
quent T cell interactions of administered aAPC.
The second approach, adoptive immunotherapy, involves the gener-
ation of antigen-speciﬁc T cells in vitro and adoptive transfer into a
patient or animal model. For example, adoptive transfer of large num-
bers of tumor speciﬁc T cells generated from melanoma cultures
can mediate complete and durable regression of even large and meta-
static tumors [7], and adoptive transfer of CMV-speciﬁc lymphocytes
has been studied as a means of limiting immunosuppression post-
transplant [14,176]. This approach has several advantages, including
complete control of T cell culture environment during growth, and
avoids the problem of attaining optimal aAPC biodistribution in vivo.
On the other hand, in vitro T cell culture is costly and labor-intensive
compared to direct aAPC administration, and can be described as
designing a “new drug” for each patient.
Moving forward, aAPCs have tremendous potential as a platform
for inducing T cell expansion and for studying fundamental aspects
of TCR organization and signaling. New breakthroughs in controlled
micropatterning and shape manipulation on the nanoscale will allow
for optimization of T cell activation mechanisms. aAPC can be produced
for many patients in bulk and designed from easily manufactured,
biocompatible platforms, creating off-the-shelf reagents that has
signiﬁcantly reduced cost compared to cellular APC. Adoptive T cellimmunotherapy is limited in part by the need to generate large
numbers (up to 1010) of tumor-speciﬁc T cells quickly and reliably
[177–179], whichmotivates the application ofmore advanced, biophys-
ical understanding of T cell activation to optimize T cell expansion. The
most rapid and robust T cell proliferation may only be possible when
micro- and nanoscale considerations are taken into account. Thus,
regardless of the therapeutic strategy chosen, size, shape, scale and sur-
face distribution should be carefully considered as elements of effective
aAPC design.
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